Superluminal Medicines Launches With $33 Million Seed Round To Fuel Its Drug Discovery Engine And Pipeline Of Small Molecule Therapeutics

Superluminal Medicines Inc., a generative biology and chemistry company, has closed a $33 million funding round led by RA Capital Management. The funding will be used to progress Superluminal’s pipeline of small molecule drug discovery programs initially focused on high-value G protein-coupled receptor (GPCR) targets. Superluminal’s platform creates candidate-ready compounds with differentiated TPPs in just months by utilizing a unique combination of human understanding, generative biology and chemistry, machine learning, and proprietary big data infrastructure.